Addex Therapeutics Ltd
ADXN
$9.47
$0.010.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 63.90K | 191.40K | 458.40K | 630.00K | 938.90K |
| Total Other Revenue | 128.30K | 84.20K | 6.80K | 7.40K | 3.90K |
| Total Revenue | 192.30K | 275.70K | 465.40K | 637.60K | 942.80K |
| Cost of Revenue | 768.60K | 859.60K | 966.40K | 1.06M | 1.38M |
| Gross Profit | -576.40K | -584.10K | -501.20K | -423.00K | -436.80K |
| SG&A Expenses | 2.21M | 2.31M | 2.62M | 3.02M | 3.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.98M | 3.17M | 3.59M | 4.08M | 4.51M |
| Operating Income | -2.79M | -2.90M | -3.12M | -3.44M | -3.57M |
| Income Before Tax | -7.13M | -6.37M | -5.57M | -5.23M | -4.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.13 | -6.37 | -5.57 | -5.23 | -4.27 |
| Earnings from Discontinued Operations | 121.80K | 15.83M | 13.14M | 10.95M | 8.79M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.01M | 9.46M | 7.57M | 5.72M | 4.52M |
| EBIT | -2.79M | -2.90M | -3.12M | -3.44M | -3.57M |
| EBITDA | -2.70M | -2.68M | -2.91M | -3.25M | -3.43M |
| EPS Basic | -0.07 | 0.10 | 0.08 | 0.05 | 0.03 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 |
| EPS Diluted | -0.08 | 0.09 | 0.07 | 0.05 | 0.03 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 395.50M | 393.29M | 392.48M | 380.47M | 359.45M |
| Average Diluted Shares Outstanding | 395.50M | 393.29M | 392.48M | 380.47M | 359.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |